GlassScriptPhysician profile
Phillip C Ginsberg
NPI 1902882715
$144,920.89
in general payments reported to CMS, 2019-2025
55 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,916 · 2021: $26K · 2022: $42K · 2023: $22K · 2024: $13K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $10K · Travel and Lodging: $5,608 · Education: $1.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,496.96 |
| Food and Beverage | $10,460.21 |
| Travel and Lodging | $5,608.48 |
| Education | $1.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $62,044.42 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $54,025.11 | 2023-2025 | Gemtesa, Orgovyx |
| Ferring Pharmaceuticals INC. | $6,972.67 | 2019-2025 | Adstiladrin |
| Amgen INC. | $4,182.95 | 2019-2025 | Prolia, Uplizna |
| Janssen Biotech, INC. | $2,437.73 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Astellas Pharma US INC | $1,948.12 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $1,452.79 | 2019-2025 | |
| Abbvie INC. | $1,412.77 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $1,280.57 | 2019-2025 | Provenge |
| Medtronic, INC. | $734.03 | 2022-2025 | Interstim |
| Coloplast Corp | $717.80 | 2019-2025 | Altis |
| Bayer Healthcare Pharmaceuticals INC. | $674.85 | 2019-2025 | |
| Urogen Pharma, INC. | $629.63 | 2020-2025 | Jelmyto |
| Tolmar, INC. | $600.55 | 2023-2025 | Jatenzo, Eligard |
| Myovant Sciences INC. | $594.35 | 2021-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Ginsberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.